Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Clinical Therapeutics

Malaria Treatment with Atovaquone-Proguanil in Malaria-Immune Adults: Implications for Malaria Intervention Trials and for Pre-Exposure Prophylaxis of Malaria

Mark E. Polhemus, Shon Remich, Bernhards Ogutu, John Waitumbi, Marc Lievens, W. Ripley Ballou, D. Gray Heppner Jr.
Mark E. Polhemus
1Walter Reed Project, United States Army Medical Research Unit, Kisumu, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mpolhemus@wrp-ksm.org
Shon Remich
1Walter Reed Project, United States Army Medical Research Unit, Kisumu, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernhards Ogutu
2Centre for Clinical Research, Kenya Medical Research Institute, Kisumu, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Waitumbi
2Centre for Clinical Research, Kenya Medical Research Institute, Kisumu, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Lievens
3GlaxoSmithKline Biologicals, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Ripley Ballou
3GlaxoSmithKline Biologicals, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Gray Heppner Jr.
4Walter Reed Army Institute of Research, Silver Spring, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01367-07
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Eighty adults in areas of Kenya where malaria is holoendemic received presumptive treatment with atovaquone-proguanil and were followed closely. The time to the first Plasmodium falciparum parasitemia was 32 days. This prolonged prophylaxis period has implications for study design when used in malaria intervention trials and cautiously suggests clinical investigation of potential preexposure prophylaxis of malaria.

Malaria intervention trials in study populations subject to continuous mosquito transmission often measure the time to parasitemia as the primary efficacy end point (1, 2, 8). In order to maximize comparability, presumptive antimalarial treatment is given to control and intervention groups to eliminate subpatent parasitemia. This may involve the use of drugs such as atovaquone and proguanil that exert causal prophylactic activity by eliminating the development of hepatic-stage parasites. The selection of presumptive drug treatment is based upon considerations of drug registration status, parasite susceptibility, practicality of administration under direct observation, half-life, and tolerability. Careful timing is required to avoid interference. Drugs must be given early enough to maximize the elimination of parasites and to avoid an antiparasitic effect during efficacy determination. Conversely, drugs must be given late enough such that there is no interval during which new parasitemias might arise prior to the start of the period of efficacy determination.

A fixed combination of atovaquone and proguanil (Malarone; GlaxoSmithKline, United Kingdom) is licensed in many countries for the prevention and treatment of acute, uncomplicated Plasmodium falciparum malaria. Three daily doses are almost 100% effective for the treatment of falciparum malaria, including highly drug-resistant strains from Southeast Asia (4). However, this dosage regimen has not been studied or received regulatory approval for presumptive treatment of malaria, especially for travelers. We report the use of atovaquone-proguanil as presumptive treatment in the context of a malaria vaccine trial in malaria-immune adults.

The protocol was approved by the Kenya Medical Research Institute Ethical Review Committee and the U.S. Army Medical Research and Materiel Command's Human Subjects Research Review Board, Fort Detrick, MD. The ClinicalTrials.gov identifier is NCT00197054. Subjects were recruited from Kombewa Division of the Kisumu West District within 1-mile-radius catchment areas around each of 13 field stations. The field stations were staffed 24 h and had radio communications and vehicles throughout the study to facilitate referral medical care. Malaria is holoendemic with peak malaria transmission periods from April to August and from October to December. Area residents receive 100 to 300 infectious mosquito bites/year (3). Malaria is mostly due to P. falciparum. After giving written informed consent, 255 healthy adults, 18 to 35 years of age, were enrolled and randomized to receive either one of two malaria vaccines or a rabies vaccine as the comparator on a 0-, 4-, or 8-week schedule. At week 7, each subject received four tablets (as a single dose), each containing 250 mg of atovaquone and 100 mg of proguanil, for three days, administered by study personnel to ensure compliance. Only the subjects in the rabies comparator group are reported here. Subjects were considered to be at risk from the day of conclusion of atovaquone-proguanil treatment until one of the following conditions occurred: development of parasitemia, loss to follow-up, emigration from the study area, withdrawal, or end of follow-up period. Passive detection of infection began immediately. Active detection of infection by scheduled weekly malaria blood films began at week 2 postcompletion of atovaquone-proguanil. The time at risk took into account absences from the study area. Subjects were followed for the first instance of P. falciparum parasitemia detected microscopically by malaria blood film. Each slide was read independently by two microscopists, each of whom examined 100 oil immersion fields before declaring a slide to be negative. Discrepancies in slide reading were adjudicated by a senior, third microscopist.

Eighty malaria-immune subjects (11 female, 69 male) completed 3 days of atovaquone-proguanil in September 2005 and were followed through January of 2006. P. falciparum parasitemia-free survival is depicted in Fig. 1. The first instance of P. falciparum parasitemia occurred 32 days after the completion of atovaquone-proguanil. The intervals for 95%, 90%, and 80% parasitemia-free survival were 45, 51, and 57 days. At the conclusion of the 17-week follow-up period, 38 of 80 (49.4%) subjects had had a first instance of P. falciparum parasitemia.

An additional ad hoc analysis examined whether treatment for malaria during the 7 weeks from the receipt of the first immunization to the time of the first dose of atovaquone-proguanil affected malaria attack rates. All malaria cases in this interval received standard oral artemether-lumefantrine treatment. There was a nonsignificant trend by log-rank analysis (P = 0.155) toward earlier new infection in those who had received artemether-lumefantrine, suggesting no confounding of results by persistent artemether-lumefantrine effects.

Our findings are consistent with a study of 65 adults in western Kenya which reported a 29-day time to initial infection after an identical 3-day treatment regimen of daily atovaquone-proguanil (10). This long antimalarial effect may be partially explained by persistent serum schizonticidal activity attributable to serum atovaquone, as was shown in in vitro assays in two serologic studies (5, 6). Future use of atovaquone-proguanil for the radical/suppressive cure of malaria in the setting of interventional trials should allow at least 28 days before initiating surveillance for efficacy.

These data may also be viewed as preexposure chemoprophylaxis using a 3-day daily treatment regimen of atovaquone-proguanil (11), an approach that might benefit short-term malaria-naïve travelers to areas where malaria is endemic. We caution that the prophylactic efficacy described here with malaria-immune subjects probably reflects both drug effect and some anti-blood-stage immunity and might be greater than would be found in malaria-naïve travelers. The use of an antimalarial drug combination in intervals that exceed the therapeutic persistence of one of the two drugs would promote the emergence and selection of parasites resistant to the drug with the longer half-life. This is a specific risk for such use of atovaquone-proguanil, since the more persistent drug atovaquone is well described to engender resistance when employed as a single agent for malaria treatment (7) or when P. falciparum is cultured in the presence of low concentrations of atovaquone (9).

Careful clinical challenge and field studies would be required to define a period of time for short-term malaria-naïve travelers to areas where malaria is endemic, likely to be in the range of 2 to 4 weeks, during which adequate protection could be expected following a single preexposure treatment course of atovaquone-proguanil. Strict one-time use and prompt return to an area where malaria is nonendemic might limit or prevent the emergence or the propagation of atovaquone-proguanil-resistant parasites.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Kaplan-Meier curve showing the time delay until P. falciparum parasitemia following treatment with atovaquone-proguanil, 1,000 mg and 400 mg, respectively, daily for 3 days in 80 malaria-immune adults in areas of western Kenya where malaria is holoendemic.

ACKNOWLEDGMENTS

We thank Colonel Alan Magill and G. Dennis Shanks and Dennis E. Kyle for their critical review and commentary. However, the opinions expressed herein are solely those of the authors.

This study was funded by the U.S. Army Medical Materiel Development Activity, Fort Detrick, MD.

Marc Lievens and W. Ripley Ballou are employees of and own stock in GlaxoSmithKline, the manufacturer of Malarone, the combination drug described in this report.

The views expressed herein are private and do not reflect official positions of the U.S. Army or U.S. Department of Defense or GlaxoSmithKline. The opinions expressed are personal and are not to be construed as use guidelines or to contradict or replace current labeling indications and guidelines for the use of atovaquone-proguanil.

FOOTNOTES

    • Received 23 October 2007.
    • Returned for modification 28 December 2007.
    • Accepted 10 January 2008.
  • Copyright © 2008 American Society for Microbiology

REFERENCES

  1. 1.↵
    Alonso, P. L., J. Sacarlal, J. J. Aponte, A. Leach, E. Macete, J. Milman, I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa, Q. Bassat, P. Aide, O. Ofori-Anyinam, M. M. Navia, S. Corachan, M. Ceuppens, M. C. Dubois, M. A. Demoite, F. Dubovsky, C. Menedez, N. Tornieporth, W. R. Ballou, and J. Cohen. 2004. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet364:1411-1420.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Bejon, P., J. Mwacharo, O. Kai, T. Mwangi, P. Milligan, S. Todryk, S. Keating, T. Lang, B. Lowe, C. Gikonyo, C. Molyneux, G. Fegan, S. C. Gilbert, N. Peshu, K. Marsh, and A. V. Hill. 2006. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials1:e29.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Bloland, P. B., T. K. Ruebush, J. B. McCormick, J. Ayisi, D. A. Boriga, A. J. Oloo, R. Beach, W. Hawley, A. Lal, B. Nahlen, V. Udhayakumar, and C. C. Campbell. 1999. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission. I. Description of study site, general methodology, and study population. Am. J. Trop. Med. Hyg.60:635-640.
    OpenUrlAbstract
  4. 4.↵
    Boggild, A. K., M. E. Parise, L. S. Lewis, and K. C. Kain. 2007. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am. J. Trop. Med. Hyg.76:208-223.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Butcher, G. A., and R. E. Sinden. 2003. Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro. Am. J. Trop. Med. Hyg.68:111-114.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Edstein, M. D., B. M. Kotecka, K. L. Anderson, D. J. Pombo, D. E. Kyle, K. H. Rieckmann, and M. F. Good. 2005. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob. Agents Chemother.49:4421-4422.
    OpenUrlFREE Full Text
  7. 7.↵
    Looareesuwan, S., C. Viravan, H. K. Webster, D. E. Kyle, D. B. Hutchinson, and C. J. Canfield. 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg.54:62-66.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Moorthy, V. S., E. B. Imoukhuede, P. Milligan, K. Bojang, S. Keating, P. Kaye, M. Pinder, S. C. Gilbert, G. Walraven, B. M. Greenwood, and A. S. Hill. 2004. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med.1:e33.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Rathod, P. K., T. McErlean, and P. C. Lee. 1997. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA94:9389-9393.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Shanks, G. D., B. O. Ragama, and A. J. Oloo. 1999. Time to reappearance of malaria parasites following various drug treatment regimens in a holoendemic area of western Kenya. Trans. R. Soc. Trop. Med. Hyg.93:304-305.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Shanks, G. D., A. J. Magill, D. O. Freedman, J. S. Keystone, D. J. Bradley, and R. Steffen. 2007. Drug-free holidays: pre-travel versus during travel malaria chemoprophylaxis. Am. J. Trop. Med. Hyg.77:1-2.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Malaria Treatment with Atovaquone-Proguanil in Malaria-Immune Adults: Implications for Malaria Intervention Trials and for Pre-Exposure Prophylaxis of Malaria
Mark E. Polhemus, Shon Remich, Bernhards Ogutu, John Waitumbi, Marc Lievens, W. Ripley Ballou, D. Gray Heppner Jr.
Antimicrobial Agents and Chemotherapy Mar 2008, 52 (4) 1493-1495; DOI: 10.1128/AAC.01367-07

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Malaria Treatment with Atovaquone-Proguanil in Malaria-Immune Adults: Implications for Malaria Intervention Trials and for Pre-Exposure Prophylaxis of Malaria
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Malaria Treatment with Atovaquone-Proguanil in Malaria-Immune Adults: Implications for Malaria Intervention Trials and for Pre-Exposure Prophylaxis of Malaria
Mark E. Polhemus, Shon Remich, Bernhards Ogutu, John Waitumbi, Marc Lievens, W. Ripley Ballou, D. Gray Heppner Jr.
Antimicrobial Agents and Chemotherapy Mar 2008, 52 (4) 1493-1495; DOI: 10.1128/AAC.01367-07
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antimalarials
Atovaquone
Malaria, Falciparum
Parasitemia
proguanil

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596